Limits...
Public funding and private investment for R&D: a survey in China's pharmaceutical industry.

Qiu L, Chen ZY, Lu DY, Hu H, Wang YT - Health Res Policy Syst (2014)

Bottom Line: There is a significantly positive correlation between public funding and private investment in different provinces of China.Further, the effect of the government was focused on private equity and venture capital investment although private fund is the mainstream of this type of investment.With rapid growth of the industry, the pharmaceutical R&D investment in China is expected to increase steadily from both public and private sources.

View Article: PubMed Central - HTML - PubMed

Affiliation: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, Block 3-406, University of Macau, Av, Padre Tomás Pereira Taipa, Macao, China. haohu@umac.mo.

ABSTRACT

Background: In recent years, China has experienced tremendous growth in its pharmaceutical industry. Both the Chinese government and private investors are motivated to invest into pharmaceutical research and development (R&D). However, studies regarding the different behaviors of public and private investment in pharmaceutical R&D are scarce. Therefore, this paper aims to investigate the current situation of public funding and private investment into Chinese pharmaceutical R&D.

Methods: The primary data used in the research were obtained from the China High-tech Industry Statistics Yearbook (2002-2012) and China Statistical Yearbook of Science and Technology (2002-2012). We analyzed public funding and private investment in five aspects: total investment in the industry, funding sources of the whole industry, differences between provinces, difference in subsectors, and private equity/venture capital investment.

Results: The vast majority of R&D investment was from private sources. There is a significantly positive correlation between public funding and private investment in different provinces of China. However, public funding was likely to be invested into less developed provinces with abundant natural herbal resources. Compared with the chemical medicine subsector, traditional Chinese medicine and biopharmaceutical subsectors obtained more public funding. Further, the effect of the government was focused on private equity and venture capital investment although private fund is the mainstream of this type of investment.

Conclusions: Public funding and private investment play different but complementary roles in pharmaceutical R&D in China. While being less than private investment, public funding shows its significance in R&D investment. With rapid growth of the industry, the pharmaceutical R&D investment in China is expected to increase steadily from both public and private sources.

Show MeSH
R&D activity of the Chinese pharmaceutical industry in recent years.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4066693&req=5

Figure 2: R&D activity of the Chinese pharmaceutical industry in recent years.

Mentions: The R&D expenditure in China’s pharmaceutical industry has increased from 162.6 million USD in 2000 to 3,249.2 million USD in 2011. The R&D intensity also fluctuated in 2010 and rose back to 1.41% in 2011 (Table 1 and Figure 2). However, it is far less than that of some other high-tech industries in China, such as the aircraft and spacecraft industry, with a ratio of 7.82%.


Public funding and private investment for R&D: a survey in China's pharmaceutical industry.

Qiu L, Chen ZY, Lu DY, Hu H, Wang YT - Health Res Policy Syst (2014)

R&D activity of the Chinese pharmaceutical industry in recent years.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4066693&req=5

Figure 2: R&D activity of the Chinese pharmaceutical industry in recent years.
Mentions: The R&D expenditure in China’s pharmaceutical industry has increased from 162.6 million USD in 2000 to 3,249.2 million USD in 2011. The R&D intensity also fluctuated in 2010 and rose back to 1.41% in 2011 (Table 1 and Figure 2). However, it is far less than that of some other high-tech industries in China, such as the aircraft and spacecraft industry, with a ratio of 7.82%.

Bottom Line: There is a significantly positive correlation between public funding and private investment in different provinces of China.Further, the effect of the government was focused on private equity and venture capital investment although private fund is the mainstream of this type of investment.With rapid growth of the industry, the pharmaceutical R&D investment in China is expected to increase steadily from both public and private sources.

View Article: PubMed Central - HTML - PubMed

Affiliation: State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, Block 3-406, University of Macau, Av, Padre Tomás Pereira Taipa, Macao, China. haohu@umac.mo.

ABSTRACT

Background: In recent years, China has experienced tremendous growth in its pharmaceutical industry. Both the Chinese government and private investors are motivated to invest into pharmaceutical research and development (R&D). However, studies regarding the different behaviors of public and private investment in pharmaceutical R&D are scarce. Therefore, this paper aims to investigate the current situation of public funding and private investment into Chinese pharmaceutical R&D.

Methods: The primary data used in the research were obtained from the China High-tech Industry Statistics Yearbook (2002-2012) and China Statistical Yearbook of Science and Technology (2002-2012). We analyzed public funding and private investment in five aspects: total investment in the industry, funding sources of the whole industry, differences between provinces, difference in subsectors, and private equity/venture capital investment.

Results: The vast majority of R&D investment was from private sources. There is a significantly positive correlation between public funding and private investment in different provinces of China. However, public funding was likely to be invested into less developed provinces with abundant natural herbal resources. Compared with the chemical medicine subsector, traditional Chinese medicine and biopharmaceutical subsectors obtained more public funding. Further, the effect of the government was focused on private equity and venture capital investment although private fund is the mainstream of this type of investment.

Conclusions: Public funding and private investment play different but complementary roles in pharmaceutical R&D in China. While being less than private investment, public funding shows its significance in R&D investment. With rapid growth of the industry, the pharmaceutical R&D investment in China is expected to increase steadily from both public and private sources.

Show MeSH